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Abstract | Prolactinomas, the most prevalent type of neuroendocrine disease, account for approximately 
40% of all pituitary adenomas. The most important clinical problems associated with prolactinomas are 
hypogonadism, infertility and hyposexuality. In patients with macroprolactinomas, mass effects, including 
visual field defects, headaches and neurological disturbances, can also occur. The objectives of therapy 
are normalization of prolactin levels, to restore eugonadism, and reduction of tumor mass, both of which 
can be achieved in the majority of patients by treatment with dopamine agonists. Given their association 
with minimal morbidity, these drugs currently represent the mainstay of treatment for prolactinomas. Novel 
data indicate that these agents can be successfully withdrawn in a subset of patients after normalization of 
prolactin levels and tumor disappearance, which suggests the possibility that medical therapy may not be 
required throughout life. Nevertheless, multimodal therapy that involves surgery, radiotherapy or both may 
be necessary in some cases, such as patients who are resistant to the effects of dopamine agonists or for 
those with atypical prolactinomas. This Review reports on efficacy and safety of pharmacotherapy in patients 
with prolactinomas.
Colao, A. & Savastano, S. Nat. Rev. Endocrinol. 7, 267–278 (2011); published online 22 March 2011; doi:10.1038/nrendo.2011.37
Introduction
Prolactin-secreting adenomas are the most pre dominant 
type of all pituitary tumors. The estimated prevalence 
is 100 prolactinomas per million adults,1 although 
Ciccarelli et al.2 reported an even higher prevalence of 
775 per million adults in Belgium. The incidence of pro-
lactino mas varies with age and sex; these tumors occur 
with the highest frequency in women aged 20–50 years, 
at which point the ratio between the sexes is estimated 
to be 10:1. In adults aged >60 years, prolactinomas occur 
with a similar frequency in both sexes.3,4 During child-
hood, pituitary tumors are rare; however, pro lactinomas 
constitute about 50% of all pituitary adenomas in 
this subpopulation.5
The most important clinical symptoms of prolactin 
excess are gonadal and sexual dysfunction as a result 
of tumor expansion in patients with macroadenomas.6 
Medical therapy of prolactinomas relies on the use of 
dopa mine receptor agonists, such as bromocriptine, 
cabergoline and quinagolide. Given the evidence-based 
efficacy of these agents, other dopamine agonists, for 
example, lisuride and terguride, as well as the serotonin 
antagonist metergoline, are rarely used. The dopamine 
agonist pergolide has been removed from the market 
because of detrimental effects on cardiac valves. In 
patients with prolactinomas, the main aims of treatment 
are the control of hormone excess and shrinkage of the 
tumor mass, together with prevention of their clini-
cal consequences. At the same time, residual pituitary 
function must be preserved or improved, and tumor 
re currence or disease progression should be prevented.1
Marked growth of untreated microprolactinomas 
(<10 mm in diameter) is uncommon. Treatment of 
asymptomatic patients with prolactinomas is, therefore, 
not always necessary.6,7 Importantly, patients with macro-
prolactinomas (>10 mm in diameter) and hypo pituitarism 
should receive standard hormone replacement therapy, 
the same as any other patient with hormone deficien-
cies. Two exceptions to this statement exist. Initiation 
of growth hormone (GH) and gonadal steroid replace-
ment should be delayed until after normoprolactinemia 
and/or tumor shrinkage are achieved,8 given that both 
GH and gonadal steroid deficiencies can be restored by 
normalization of prolactin levels compared with other 
deficiencies of the pituitary axis.
This Review summarizes the data on medical treat-
ment of patients with prolactinomas. In particular, we 
will focus on previous findings of an association between 
cardiac valve disease and treatment with dopamine ago-
nists in patients with hyperprolactinemia and on the pos-
sibility that permanent control of prolactin levels can be 
achieved after withdrawal from these drugs.
Treatment profile of dopamine agonists
Dopamine agonists can be divided into two classes: the 
ergot derivatives, which include bromocriptine, per-
golide and cabergoline, and the non-ergot derivatives, 
for example, quinagolide. Treatment with dopamine ago-
nists causes a clinically relevant decrease in the size of 
prolactinomas through a number of mechanisms. First, 
by reducing cell volume indirectly through inhibition of 
hormone secretion in an early phase; second, via inhibi-
tion of gene transcription and prolactin synthesis at a 
later stage; and finally, by inducing perivascular fibrosis 
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and cell necrosis.9 A more extensive discussion of this 
topic can be found elsewhere.6,10
Bromocriptine
Bromocriptine, the oldest drug for medical treatment 
of prolactinomas, was introduced into clinical practice 
25 years ago.6,9–11 This ergot alkaloid is derived by semi-
synthesis and has D2 receptor agonist and D1 receptor 
antagonist properties. Although the most widely used 
drug in patients with hyperprolactinemia is cabergoline, 
bromocriptine is still frequently prescribed as the best 
alternative to cabergoline.12 Compared with cabergoline, 
bromocriptine has a shorter half-life and is administered 
two or three times daily. Once daily administration may 
be recommended in some patients who are highly sensi-
tive to the drug. The therapeutic dose generally ranges 
between 2.5 mg and 15.0 mg per day, with most patients 
receiving 7.5 mg or less.13–19 In patients with treatment 
resistance, bromocriptine doses can be increased to 
20–30 mg per day.17
In 80–90% of patients with microprolactinomas and 
in 70% of individuals with macroprolactinomas, bromo-
criptine treatment controls hyperprolactinemia and thus 
restores gonadal function and reduces tumor size.10,11 
Tumor mass effects, such as headaches and visual field 
defects, improve within days after initiation of bromo-
criptine therapy in most patients. Notably, gonadal and 
sexual function can ameliorate even if prolactin levels are 
still above the normal range. In general, pro lactinomas 
remain sensitive to bromocriptine and delayed resis-
tance is rare; however, treatment withdrawal can often 
result in recurrence of hyperprolactinemia (see below). 
Normalization of prolactin levels is followed by improve-
ments in BMD, both in women13 and in men,15 and 
improvement of semen quality.20
Adverse effects of bromocriptine include nausea, 
vomiting, postural hypotension, headache and dizziness, 
which are caused by the rapid intestinal absorption of the 
drug. In the past, various formulations of bromo criptine 
were developed to improve tolerability, for example, long-
acting and repeatable formulations for intra muscular 
injection, an intranasal powder formulation or tablets 
Key points
 ■ Medical treatment of prolactinomas with cabergoline, quinagolide or 
bromocriptine is very efficacious; cabergoline has demonstrated superiority  
in efficacy to other drugs in many studies
 ■ Cardiac valve disease induced by cabergoline treatment in patients with 
hyperprolactinemia is still a matter of debate
 ■ In the absence of unequivocal proof excluding a negative effect of  
cabergoline in patients with hyperprolactinemia, all patients who receive  
long‑term cabergoline treatment should undergo regular echocardiographic 
follow‑up
 ■ Long‑term discontinuation of cabergoline or bromocriptine in patients with 
hyperprolactinemia of any cause has shown a variable rate of tumor recurrence; 
predictors of recurrence before cabergoline withdrawal are tumor diameter and 
prolactin levels
 ■ Resistance to dopamine agonists is a rare phenomenon that characterizes  
a group of tumors that generally manifest with a more aggressive behavior  
than usual
for intravaginal administration. Despite initial promising 
data,21,22 none of these formulations has been introduced 
into the market.
Cabergoline
In contrast with bromocriptine, which has a partial 
affinity for the D1 receptor, cabergoline is a selective 
D2  eceptor agonist with widely known beneficial effects 
in resolving hyperprolactinemia.23 Chronic cabergoline 
treatment at a twice-weekly dose of 1 mg significantly 
reduces serum prolactin levels in up to 95% of women 
with hyperprolactinemia.24 In a large study that included 
data from 455 patients,25 cabergoline treatment achieved 
normalization of prolactin levels in 86% of 425 patients, 
that is, in 92% of 244 patients with idiopathic hyper-
prolactinemia or microprolactinomas and in 77% of 
181 patients with macroprolactinomas. Only 13% of the 
patients included in this study reported clinically rele-
vant adverse effects, and only 4% of all patients discon-
tinued treatment as a result of these adverse events.25 In 
a comparative retrospective study by Di Sarno et al.,26 the 
efficacy of cabergoline was demonstrated to be greater 
than that obtained using bromocriptine.
At treatment start, the median dose of caber goline 
is usually 0.5 mg per week in patients with idiopathic 
hyperprolactinemia or microprolactinomas.26 For indivi-
duals with macroprolactinomas, treatment with caber-
goline should be initiated at very low doses (0.25 mg 
weekly) to avoid a too rapid effect on tumor shrink-
age,27,28 as this emergency condition can cause intra-
tumoral hemorrage that requires immediate surgical 
intervention. The dosage is then increased according to 
the individual patient’s condition in order to control pro-
lactin excess. After 12–24 months of caber goline therapy, 
a reduction in tumor mass (by ≥20% compared with 
baseline values) is observed in >80% of cases, whereas 
total tumor disappearance occurs in 26–36% of patients. 
Cabergoline treatment of patients previously treated 
with bromo criptine or quinagolide has been reported 
to cause a further shrinkage of the tumor in the major-
ity of indivi duals, even in those considered resistant to 
dopamine agonists.29 As expected, the rate of control of 
prolactin excess and decline in tumor size was higher 
in drug-naive patients than in previously treated indivi-
duals (Figure 1).29 Available data of caber goline treat-
ment in men with hyperprolactinemia are still limited, 
as pro lactinomas in men are rarer than in women.6,30 
How ever, the efficacy of cabergoline treatment has 
been demonstrated in male patients, not only for the 
control of prolactin levels and tumor size,31 but also 
for the improvement of fertility by normalizing sperm 
quality20,31 and sexual function.32 In less than 5% of the 
patients, hyperprolactinemia may persist despite increas-
ing cabergoline dosage.17,33–36 Some studies have reported 
negative effects of cabergoline on cardiac valves. These 
data are discussed in a following section.
Quinagolide
Quinagolide, a non-ergot derived dopamine agonist 
with selective D2 receptor activity, is available for oral 
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administration in a single daily dose. In women with 
hyperprolactinemia, quinagolide treatment is reported 
to control prolactin excess and tumor growth.37 In 13 of 
14 men with hyperprolactinemia and associated abnor-
malities of sperm quality, treatment with quinagolide 
over 3 months was associated with normalization of 
prolactin levels and sperm parameters.38 In addition, 
quinagolide treatment caused a reduction of tumor mass 
by at least 30% from baseline size in 8 of 13 men with 
macroprolactinomas.38 Moreover, quinagolide treatment 
over 24 weeks decreased tumor size in 21 patients, as 
well as restored regular menses in 11 of 15 premeno-
pausal women and sexual function in five of seven men 
enrolled in a prospective, multicenter trial.39
On the basis of these results, quinagolide treatment 
might be considered as effective as bromocriptine treat-
ment. After 24 weeks, 81% of patients experienced bio-
chemical control of prolactin excess with quinagolide 
compared with 70% with bromocriptine. Both drugs 
restored menses and fertility and controlled galactorrhea 
in a similar proportion of patients;39 however, the safety 
profile was more favorable for quinagolide.39,40 None-
theless, compared with cabergoline, quinagolide was less 
efficacious and adverse effects were more frequent,26,41,42 
although quinagolide does not seem to induce cardiac 
valve disease.43 Quinagolide is currently available for 
treatment of hyperprolactinemia in several European 
countries and in Canada but not in the USA.
Other drugs
Pergolide, an ergot derivate with D1 and D2 agonist 
activity approximately 100-fold that of bromocriptine, 
controlled prolactin excess and reduced tumor size in 
the majority of newly diagnosed patients with macro-
prolactinomas.44,45 However, pergolide was withdrawn 
from the market in 2007 because of adverse effects on 
cardiac valves.
Lisuride hydrogen maleate, another ergot derivate, was 
investigated for its ability to inhibit prolactin secretion in 
experimental hyperprolactinemia.46,47 Terguride, an ana-
logue of lisuride, normalized prolactin levels and reduced 
tumor mass in a limited number of patients with micro-
prolactinomas.48 Metergoline, a 5- hydroxytryptamine 
receptor 1B (HTR1B) and HTR1D antagonist, was also 
used to prevent lactation in the past.
Cardiac valve disease
The safety of pergolide and cabergoline has been ques-
tioned given the results of two studies in patients with 
Parkinson disease, which showed an increased risk 
of valve regurgitation, that is, the abnormal seeping of 
blood from the ventricle, through the valve, into the 
atrium when the ventricle contracts, which causes 
regurgitation of blood back into the atrium.49,50 Besides 
its affinity for D2 dopa mine receptors, cabergoline also 
possesses a high affinity for HTR2B, a receptor located 
on heart valves. Activation of HTR2B can lead to mito-
genesis and fibroblast proliferation, which in turn can 
cause thickening, retraction and stiffening of the valve 
apparatus. These changes induce inadequate closure of 
the valves and clinically relevant regurgitation that is 
asymptomatic in most cases.
On histopathology, cardiac valves from patients treated 
with pergolide or cabergoline for Parkinson disease show 
abnormalities similar to those found in patients with car-
cinoid disease who are treated with ergot alkaloid drugs 
(ergotamine, methysergide) against migraine or anorec-
tic drugs (fenfluramine).51 In the healthy population, 
the prevalence of valve regurgitation is highly variable, 
ranging from 24% to 96% for tri cuspid re gurgitation 
and between 10% and 80% for mitral regurgita tion.52,53 
Clearly, population studies include patients with hyper-
tension as well as those with other cardiac risk factors, 
thus, their results are hardly comparable with those of 
patients with hyperprolactinemia, who are predominant ly 
women of young age.54
Nevertheless, 11 studies assessed the potential associa-
tion between valve regurgitation and the use of caber-
goline in patients treated for prolactinoma (Table 1).In 
total, 795 patients treated with cabergoline at a median 
cumulative dose of 290 mg and a median duration of 
59 months and 1,202 healthy control indivi duals were 
included in these studies. Five of these studies did not 
report any relevant cardiac findings, although increased 
prevalence of regurgitation in any valve was reported 
in five studies, and one study reported an increased 
tenting area of the mitral valve (Table 1). We have 
reported an increased risk of tricuspid regurgitation 
in patients treated with cabergoline over at least 1 year, 
with a small but significant association with higher 
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Figure 1 | Prevalence of normal prolactin levels and of tumor shrinkage >80% 
compared to basal volume in patients with macroprolactinomas grouped according 
to previous treatment with bromocriptine or quinagolide and then treated with 
cabergoline (0.25–3.5 mg weekly) for 1–3 years. Responsive: 28 patients, 
previously treated with bromocriptine or quinagolide for 1–5 years, who achieved 
normoprolactinemia and restoration of gonadal function, but no longer treated with 
these drugs because of poor compliance or because the drug was not longer 
available. Resistant: 37 patients shown to be resistant or hyporesponsive to 
bromocriptine, quinagolide or both. Intolerant: 19 patients previously shown to be 
intolerant to bromocriptine treatment. Naive: 26 untreated patients. Figure is 
based on data from Colao and colleagues.29
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cabergoline dosages (Figure 2).55 Subsequently, several 
systematic reviews56–59 that included dif ferent studies 
showing abnormalities in valve physiology did not sup-
port the existence of an association between the long-
term treatment of prolactinoma with cabergoline and 
clinically relevant valvular regurgitation. Nonetheless, 
the investi gators conclude that data published thus far 
are inconclusive. Other studies, preferably prospec-
tive and on large series of patients who are followed 
up by echocardio graphy over a long-term period, are 
needed before any conclusion on the detrimental effect 
of caber goline on cardiac valve disease in patients with 
prolactinom as can be drawn.
Additionally, only limited data are available on bromo-
criptine, which apparently has no effect on cardiac valve 
disease in patients with hyperprolactinemia.59 Con-
versely, in patients with Parkinson disease, bromo-
criptine treatment is associated with a similar risk of 
cardiac valve disease as pergolide, with a clear dose-
dependent effect.60 No detrimental effects on cardiac 
valve disease are expected with quinagolide, as this drug 
is a non-ergot derivate, although no data are currently 
available.61 Importantly, withdrawal of cabergoline or 
pergolide therapy has been associated with improvement 
or no further deterioration of cardiac valve disease.62,63 
An important contribution to this discussion has been 
published by Gu and co workers,64 who determined a bias 
in reading echocardiograms. In light of this finding, the 
studies showing detrimental effects of cabergoline on 
cardiac valve disease should be reanalyzed with a more 
careful study design and participating cardiologists 
blinded to the identity of patients or controls.
Dopamine agonist withdrawal
In the past, termination of dopamine agonist therapy 
has by and large resulted in a greater incidence of recur-
rent hyperprolactinemia compared with that observed 
after surgery.18,26,65–76 As shown in Table 2, most patients 
showed recurrence of hyperprolactinemia after treatment 
withdrawal compared with 6.3–50.0% of those surgically 
treated for microprolactinomas.6
Table 1 | Cardiac valve disease in patients with hyperprolactinemia treated with cabergoline
Author Year Patients Controls Cumulative 
dose (mg)
Treatment 
duration 
(months)
Cardiac findings
Bogazzi et al.55 2008 100 100 279 67 No relevant findings
Colao et al.56 2008 50 50 414 74 Increased prevalence of moderate 
tricuspid regurgitation
Vallette et al.126 2008 70 70 282 55 No relevant findings
Devin et al.127 2008 45 0 NA 39 7% abnormalities
Lancellotti 
et al.128
2008 102 51 204 79 Significant increase in mitral tenting area
Kars et al.129 2008 47 78 363 62 Increased prevalence of mild tricuspid 
regurgitation; more mitral and aortic 
calcification and tricuspid thickening 
Wakil et al.130 2008 44 566 311 45 Increased prevalence of mild tricuspid  
and pulmonic regurgitation
Herring et al.131 2009 50 50 443 79 No relevant findings
Nachtigall 
et al.132
2009 100 100 253 48 Mild increase in tricuspid regurgitation  
in female patients
Lafeber et al.133* 2010 115 115 227 115 No relevant findings
Tan et al.134 2010 72 72 126 53 No relevant findings
*This study included 19 patients with a diagnosis of acromegaly. Abbreviation: NA, not available.
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Figure 2 | Prevalence of valve regurgitation in patients with 
hyperprolactinemia treated with cabergoline for a median 
period of 74 months. The P value is derived from a Chi 
square analysis comparing prevalence of valve 
regurgitation in 22 patients treated with cabergoline at 
doses ≤1 mg weekly with 28 patients treated with higher 
doses. Figure is based on data from Colao and 
colleagues.55 Abbreviation: CAB, cabergoline.
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Criteria for drug withdrawal
Previous studies have some limitations in the small series 
of patients assessed and lack of criteria for treatment 
withdrawal (Box 1). In 2003, a group of 200 patients with 
hyperprolactinemia underwent caber goline withdrawal 
following a stringent protocol.77 In this study, pro lactin 
levels were normal after withdrawal of caber goline 
for a maximum period of 5 years in >60% of patients, 
independent of tumor size at baseline.77 After 5 years of 
drug withdrawal, the Kaplan-Meier estimator of recur-
rence of hyperprolactinemia was 24.0%, 32.6% and 
43.3% in patients with nontumoral hyperprolactinemia, 
those with microprolactinomas and those with macro-
prolactinomas, respectively.77 Interestingly, despite 
recurrence of hyperprolactinemia, no evidence of tumor 
regrowth was found in any patient, as documented by 
serial MRI.77 Symptoms of gonadal dys function recurred 
in only 10 women (22.2%) and seven men (38.9%).77 The 
maximal tumor diameter during cabergoline treatment 
was the most effective predictor of persistent hyper-
prolactinemia after drug withdrawal. Each additional 
mm of maximal tumor diameter, as measured on MRI 
before treatment withdrawal, increased the risk of recur-
rence of hyperprolactinemia by 19%.77 Taking these 
results into consideration, dopamine agonist withdrawal 
could be performed in order to spare patients from 
unnecessary treatment, particularly in indivi duals with 
no remnant tumor visible during treatment. One limita-
tion of these results is the use of very strict selection 
criteria that apply only to a subset of patients with pro-
lactinoma (Box 1). Accordingly, only 56% of the entire 
patient population with hyperprolactinemia would be 
eligible to undergo cabergoline withdrawal.
In another retrospective study, Biswas et al.78 reported 
a prevalence of normalized prolactin levels after 
bromo criptine or cabergoline withdrawal of 31% and 
50%, respectively (Table 2). Furthermore, all patients 
with remnant macroprolactinomas at treatment with-
drawal, as well as 70% of those with remaining micro-
prolactinomas, had recurrence of hyperprolactinemia 
after 96 months, suggesting that only patients with a 
negative MRI scan may undergo treatment withdrawal.6 
Kharlip et al.79 found an overall recurrence of 54%, a 
rate higher than that observed in our series;77 52% of 
31 patients with microprolactinoma, 55% of 11 patients 
with macroprolactinoma and 75% of four patients with 
nontumoral hyperprolactinemia had recurrence within 
2–48 months of cabergoline withdrawal. The re searchers 
confirmed that size of tumor remnant before drug 
withdrawal predicted recurrence and that none of the 
Table 2 | Dopamine agonist withdrawal
Reference Number of patients Drug Treatment 
duration 
(months)
Normal 
prolactin (%)
Follow-up 
duration 
(months)Total Micro Macro NTH
Johnston et al.65 37 NA NA 19 BRC 12–72 5.4 0.5
Zarate et al.66 16 NA NA 0 BRC Mean 24 37.5 24
Moriondo et al.67 36 36 0 0 BRC Mean 12 22.0 Up to 30
Johnston et al.68 13
2
5
1
6
1
2
0
BRC
PER
Mean 44
24
7.7
0
1.0–12.5
2
Maxson et al.69 7 7 0 0 BRC >12 0 2
Wang et al.70 24 15 4 5 BRC Mean 24 21.0 12–48
Winkelmann et al.71 40 NA NA NA BRC NA 18.4 5–25
Rasmussen et al.72 75 NA NA NA BRC Mean 24 44.0 >6
Van’t Verlaat et al.73 12 0 12 0 BRC Median 60 8.3 12
Ferrari et al.74 65 42 7 15 CAB Median 14 31.3 (year 1)
66.7 (year 2)
3–24
Muratori et al.75 26 26 0 0 CAB 12 19.0 38–60
Cannavò et al.76 37 26 11 0 CAB 24 13.5 12
Di Sarno et al.26 39
39
23
23
16
16
0
0
CV
CAB
12
12
0
10.2
0.5–2
12
Passos et al.18 131 62 69 0 BRC Mean 47 20.6 Mean 44
Colao et al.77 200 105 70 25 CAB >24 68.5 24–60
Biswas et al.78 22
67
22
67
0
0
0
0
BRC
CAB
Median 36
Median 36
50.0
31.3
>12
>12
Colao et al.80 227 27 115 79 CAB >24 58.6 24–96
Kharlip et al.79 46 31 11 4 CAB 52 46.0 2–48
Huda et al.81 40 40 0 0 DA Mean 108 22.5 >12
Abbreviations: BRC, bromocriptine; CAB, cabergoline; CV, quinagolide; DA, dopamine agonists; Macro, macroadenoma; Micro, microadenoma; NA,  
not applicable; NTH, nontumoral hyperprolactinemia, PER, pergolide. Permission obtained from The Endocrine Society © Gillam et al. Endocr. Rev. 27,  
485–534 (2006).
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tumors enlarged in the patients experiencing recurrence. 
Moreover, Kharlip et al.79 showed that 28% of patients 
had symptoms of hypogonadism after drug withdrawal.
The major differences between our study77 and the 
one by Kharlip et al.79 are the number of patients ana-
lyzed, which was four times larger in our study, the use 
of cabergoline alone in our study, and methods adopted 
for withdrawal of cabergoline that occurred before study 
entry in the trial by Kharlip and colleagues. A subsequent 
analysis of our study population,80 showed that normal-
ized prolactin levels persisted, with no evidence of tumor 
regrowth, 24–96 months after cabergoline withdrawal 
in most patients with nontumoral hyperprolactinemia 
and microprolactinomas and in approximately 50% of 
those with macroprolactinomas. A nadir prolactin level 
of <235 pmol/l, equal to 5.4 µg/l, and a maximal tumor 
diameter of 3.1 mm at the time of cabergoline withdrawal 
successfully predicted remission of hyperprolactinemia 
in 80% of patients.80
The latest analysis of this patient series (Figure 3), 
10 years after cabergoline withdrawal, showed that 78% 
of patients with nontumoral hyperprolactinemia main-
tained normal prolactin levels during follow-up. Of the 
patients with microprolactinoma or macroprolactinoma, 
only 51% and 34%, respectively, had normo prolactinemia 
(Figure 3). In analogy with our previous data,77 and with 
results reported by Kharlip et al.79 and Huda et al.,81 
prolactin levels at the last follow-up examination or at 
diagnosis of recurrence of hyperprolactinemia corre-
lated with the nadir prolactin level during treatment 
(Figure 4a), with the nadir tumor volume before with-
drawal (Figure 4b) and with the duration of cabergoline 
treatment (Figure 4c). In the near future, we will complete 
the analysis of a large series of patients under going caber-
goline withdrawal with a follow-up of 10 years in order to 
compare our results with those obtained after surgery.
Spontaneous remission
Pregnancy82 and menopause83 are conditions associ ated 
with spontaneous remission of hyper prolactinemia; 
how ever, neither was associated with an increased preva-
lence of normalized prolactin levels after caber goline 
with drawal.77 Remission of hyperprolactinemia has 
also been reported in untreated patients. In particular, 
sponta neous remission was noticed in 32–55% of patients 
with microprolactinomas.84–87 However, although dis ease 
regression might occur in one-third of patients with 
micro prolactinomas or nontumoral hyper prolactinemia 
according to the natural disease history, this event is less 
likely to occur in patients with macroprolactinomas, 
and, thus, regression is more probable with previous 
ca bergoline treatment.
Persistent remission
According to Dekkers et al.,88 the proportion of patients 
who achieve normoprolactinemia in the long term after 
dopamine agonist withdrawal is 21%. A stratified analy-
sis showed more frequent persistence of normal pro-
lactin levels after treatment withdrawal in patients with 
idiopathic hyperprolactinemia (32%, 95% CI 5–80%) 
than in those with microprolactinomas (21%, 95% CI 
10–37%) or macroprolactinomas (16%, 95% CI 6–36%). 
Factors associ ated with treatment success were the length 
of treatment duration and the use of cabergoline, albeit 
the latter factor did not achive statistical significance. In 
conclusion, withdrawal of cabergoline can be performed 
in patients who achieve normoprolactinemia and com-
plete tumor disappearance, as determined by MRI, after 
at least 2 years of treatment, to avoid unnecessary over-
treatment.89 Patients should be followed up very strictly 
during the first year after withdrawal, as recurrence of 
hyperprolactinemia is highest during this time. Patients 
with macroadenomas require closer monitoring for 
recurrent hyper prolactinemia and tumor regression than 
others, as tumor regrowth may compromise vision.77
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Figure 3 | Kaplan‑Meier estimation of recurrence of hyperprolactinemia after 
10 years of cabergoline withdrawal. The study population consisted of 27 patients 
with nontumoral hyperprolactinemia, 115 with microprolactinomas and 79 with 
macroprolactinomas.80 Significance was obtained using the log‑rank Manter–Cox 
test. Adapted with permission obtained from John Wiley and Sons © Colao, A. et al. 
Clin. Endocrinol. (Oxf.) 67, 426–433 (2007).
Box 1 | Criteria for cabergoline withdrawal77
 ■ Serum prolactin levels in the normal range (<1,087 pmol/l, equal to 25 µg/l, 
in women and <652 pmol/l, equal to 15 µg/l, in men) during treatment with 
cabergoline (minimal treatment duration: 2 years)
 ■ No remnant tumor visible on MRI or a reduction in tumor size by ≥50% 
compared with baseline size during treatment with cabergoline (minimal 
treatment duration: 2 years)
 ■ In case of tumor persistence, patients are considered for withdrawal of 
cabergoline only if the outer border of the tumor is ≥5 mm or more from the 
optic chiasm, without evidence of invasion of one or both cavernous sinuses  
or any other critical area
 ■ To minimize the risk of errors in reading MRI scans, all patients continued to 
receive cabergoline therapy for 12 months after fulfilling the withdrawal criteria 
and before withdrawal of the medication (total minimal treatment duration: 
3 years before withdrawal)
 ■ Patients were required to continue follow‑up after withdrawal for at least 
24 months
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Aggressive prolactinomas
Aggressive pituitary tumors are classically defined as 
atypical pituitary tumors with extensive invasion of 
surround ing anatomical structures and/or rapid growth 
and/or giant size. The presence of subcranial, brain or 
systemic metastases is diagnostic of pituitary carci-
noma.90,91 In a neurosurgical series, aggressive pituitary 
tumors were found in 15% of all resected tumors, of 
which 11% were prolactinomas.92 Aggressive pituitary 
tumors are notoriously difficult to manage owing to their 
size, invasiveness, speed of growth and high frequency 
of recurrence. In general, aggressive pituitary tumors are 
associated with poor prognosis, as therapeutic options 
are limited.90,91 In the case of prolactinomas, atypical, 
aggressive tumors are found more frequently in men 
than women.3,34,92–94
More often than not, atypical prolactinomas are 
macro adenomas with invasion to structures surround-
ing the pituitary gland, as visible on MRI.92 How ever, 
the prolactinoma is not the most frequent histotype 
of atypical pituitary adenomas, as reported by Zada 
and colleagues.92 Of 121 patients who underwent 
trans sphenoidal surgery, two patients with macro-
prolactinomas were diagnosed as having an atypical 
pituitary tumor; one of these two patients was found to 
be resistant to dopamine agonists.
Hystological characteristics
Standard histology and electron microscopy are nor-
mally unable to distinguish benign from aggressive, 
atypical invasive adenomas, which exhibit more malig-
nant behavior, with a variable degree of nuclear atypia 
and cellular pleomorphism.90,91 The 2004 WHO clas-
sification defines atypical pituitary adenomas as: an 
MIB-1 proliferation index >3%, excessive p53 immuno-
reactivity and increased mitotic activity.92 However, a 
distinction between progressive and/or metastatic 
lesions and benign adenomas by analyzing mitotic 
indices, which are consistently higher in the former, is 
not always easy, as no particular threshold exists. Of all 
different bio logical markers associated with invasive 
potential of pituitary adenomas, the percentage of cells 
in the S phase of the cell cycle, which represents the 
proliferation rate, is particularly important.93 The Ki-67 
index, which can be obtained using the MIB-1 antibody, 
corre lates best with tumor invasiveness and potentially 
with prognosis,95 as Ki-67 labeling is increased in malig-
nant and invasive tumors compared with benign ade-
nomas (11.9% versus 4.7% versus 1.4%, respectively).93 
Additionally, prognostic value is also attributed to p53 
expression, which is analyzed in a semiquantitative 
way by immuno histochemistry. However, presence or 
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Figure 4 | Correlation analysis of data obtained by 227 
patients included in the study by Colao and colleagues.80 
Prolactin levels at last follow‑up examination or on 
recurrence of hyperprolactinemia compared with a | nadir 
prolactin levels before cabergoline withdrawal; b | nadir 
tumor diameter before cabergoline withdrawal and  
c | duration of cabergoline treatment before its withdrawal.
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absence of p53 immuno staining is more indicative than 
the actual degree of staining to indicate aggressive and 
particularly malignant behavior.96 Immunostaining 
of p53 in combination with an increased Ki-67 index 
may have a higher predictive value than either method 
alone.90 Additionally, the microvascular density, indi-
cated as a marker of angiogenesis, is also associated 
with metastatic potential and is considered to possess 
an independent role as predictor of patient survival.97 
A distinction between benign and aggressive, invasive 
or malignant tumors based on microvascular density is 
unclear, although pituitary carcinomas have a higher 
microvascular density than benign tumors. Moreover, 
microvascular density did not show any corre lation with 
Ki-67 labeling.97
Of all the other markers investigated to differen-
tiate benign from atypical tumors—including matrix 
metallo proteinase activity, cyclins and inhibitors of the 
cell cycle, markers of apoptosis and/or chromosomal 
gains and losses—a variable relevance has been found 
in several pituitary tumor types, with none of the men-
tioned pathways demonstrating a particular role in the 
differential diagnosis.91
Resistance to dopamine agonists
A minority of patients with hyperprolactinemia do not 
achive biochemical control of prolactin excess and/or 
do not have a reduction in tumor mass during treatment 
with dopamine agonists.6 A comprehensive definition of 
dopamine agonist resistance is still lacking. Several pro-
posals have been provided in the literature, such as failure 
to normalize prolactin levels, failure to reduce prolactin 
levels sufficiently to achieve ovulation or to 50% of base-
line levels, or failure to reduce tumor mass during treat-
ment with elevated dosages of these drugs.6,98 Prevalence 
of resistance to dopamine agonists, in particular to the 
most used dopamine agonist cabergoline, is low, and 
reported in 10% of patients with micro prolactinomas 
and 18% of those with macro prolactinomas.17 Evidently, 
the number of patients defined as drug resistant depends 
on the administered dose. In our experience, we did not 
find beneficial effects in increasing dosage of caber-
goline over 3.5 mg per week, but other investigators 
have suggested to increase the drug stepwise until a 
decrease of pro lactin levels is observed.35,98 Resistance 
was reported to be more common in patients with tumor 
extension into the caver nous sinuses,34 and generally, 
atypical prolactinomas extend over the pituitary fossa.92 
Dopamine agonist resistance is a complex phenomenon 
owing to several abnormalities of the D2 receptor,
98 both 
in quantitative expression and affinity to the ligand, so 
that targeting this receptor subtype is not followed by 
prolactin suppression and tumor shrinkage. A more 
detailed description of resistance to dopamine agonists 
is reported elsewhere.6
Late resistance
A particular condition that represents a negative prognos-
tic factor in patients with prolactinomas is the occurrence 
of late resistance.99 Patients who initially demonstrate a 
successful response to dopamine agonist therapy but 
develop a delayed resistance should be treated aggres-
sively, as this phenomenon might be associated with 
malignant transformation of the prolactinoma.99–101 
One patient, who deceased because of a malignant pro-
lactinoma characterized by late resistance, developed 
abnormal expression of guanine nucleotide-binding 
protein Gsα during the late stage, showing a pheno type 
of a mixed GH–prolactin-secreting tumor.102
Increasing dopamine agonist dosage
A patient who does not achieve control of prolactin 
levels generally receives an increased dosage of caber-
goline.98 Ono et al.35 found that this drug normalized 
pro lactin levels in all but one patient (0.7%). The rate of 
pro lactin normalization increased from 34.6% to 73.1% 
and 88.5% when the dosage of cabergoline was raised 
from 3 mg per week to 6 mg and 9 mg weekly, respec-
tively, finally reaching 96.2% at the highest dose of 12 mg 
per week.35 Di Sarno et al.17 determined that 10 of 56 
patients (17.9%) with macroadenomas and six of 60 
patients (10%) with microadenomas required increased 
doses of caber goline. The maximal dose administered 
to drug-resistant patients was 7 mg weekly; how ever, 
normo prolactinemia was not achieved in any of the 
drug-resistant patients with this dosage.17
Delgrange et al.36 reported prolactin normalization in 
115 out of 122 patients (94%), with most patients (83%) 
achieving control with a dose of ≤1.5 mg cabergoline 
per week. Increase of the cabergoline dose higher than 
1.5 mg weekly induced control of prolactin levels in 19 of 
26 poor responders and nonresponders and, in analogy 
with Di Sarno et al.,17 the investigators did not achieve 
a higher success rate when increasing the dosage up to 
3.5 mg per week. In a single case report, use of extremely 
elevated doses of cabergoline in combination with testo-
sterone and aromatase inhibitor therapy was successful 
in controlling both prolactin levels and the associated 
hypogonadism.103 This study indicates that when testo-
sterone replacement is required in male patients with 
prolactinoma, a negative influence of estrogen status 
on the prolactin-inhibitory effect cannot be completely 
ruled out.
Experimental treatments
Somatostatin analogues
Several experimental treatments used in selected case 
reports or in experimental settings have not yet been 
included in routine clinical practice. In summary, somato-
statin analogues are widely used for the treatment of 
GH-secreting pituitary adenomas and neuroendocrine 
tumors104 but not for prolactinomas. Somatostatin ana-
logue therapy is successful in patients with acromegaly 
and neuroendocrine tumors because of a high density 
of somatostatin receptor subtype 2 (SSTR2) and SSTR5 
on the cell surface of these tumors. Although somato-
statin suppresses prolactin secretion in vitro in cultured 
prolactinomas,105 neither somatostatin nor octreotide 
are able to inhibit prolactin levels in patients with pro-
lactinomas.106,107 Owing to a relative abundance of SSTR5, 
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rather than of SSTR2, in prolactinomas,108,109 the novel 
compound pasireotide, which is characterized by a high 
affinity for SSTR1, SSTR3 and SSTR5, is expected to 
be able to treat some prolactinomas resistant to dopa-
mine agonists in the near future. In primary cultures 
from both mixed GH-prolactin secreting adenomas 
and pure  prolactin-secreting adenomas, Hofland et al.109 
have demon strated a greater potency of pasireotide than 
octreo tide in suppressing prolactin secretion.
Hybrid molecules
Some chimeric compounds that contain structural ele-
ments of both somatostatin and dopamine in a single 
molecule have been developed. These hybrid molecules 
possess a potent and selective agonist activity for both 
SSTR2 and the D2 receptor. Their clinical use is based on 
the evidence that SSTR2 and D2 receptor heterodimerize 
in the presence of appropriate ligands, thereby inducing 
the formation of a hybrid receptor showing enhanced 
inhibitory activity of adenyl cyclase.110 BIM23A387, a 
chimeric somatostatin–dopamine molecule, was shown 
to strongly suppress prolactin secretion in vitro.111,112 No 
data are yet available in patients with pituitary tumors 
using this drug. Although trials with this drug have 
been discontinued, a new chimera with identical in vitro 
results to BIM23A387 is under development.
Selective estrogen receptor modulators
Other treatment modalities address estrogen secretion 
and/or function because of known effects of this hor mone 
on stimulation of prolactin secretion and pro liferation 
of pituitary lactotrophs both in vitro and in vivo.113 The 
discordant findings reported in studies on selective estro-
gen receptor modulators are potentially owing to use of 
different dosages, duration of treatment and behavior or 
characterstics of individual tumors.6 Fulvestrant, a new 
estrogen receptor antagonist without agonist activity, 
decreased prolactin levels by 88% and attenuated tumor 
growth by 41% in rats with sub cutaneous sommato-
lactotroph tumors.114 Treatment with tamoxifen for 5 days 
in eight patients with giant invasive prolactinomas, only 
mildly inhibited prolactin secretion.115 Neither ral oxi-
fene nor fulvestrant have been tested in vivo in humans 
with prolactinomas.
Prolactin-receptor antagonists
Prolactin-receptor antagonists might constitute another 
possible treatment approach as these agents could block 
the proliferative effects of autocrine-derived prolactin, 
thereby improving the clinical consequences of persis-
tently elevated prolactin levels.116 However, the effects of 
prolactin-receptor antagonists are still not proven, both 
in normal and adenomatous human lactotrophs.
Temozolomide
Special attention has been given to temozolomide, an 
alkylating chemotherapeutic drug, indicated for treat-
ment of glioblastoma,117 as some efficacy of this drug 
has also been found in patients with neuroendocrine 
tumors118 and in some with aggressive pituitary tumors 
or carcinomas.119 The efficacy of temozolomide seems 
to depend on the expression of the DNA repair protein 
MGMT.120 As described by Raverot et al.,119 eight 
patients, five with pituitary carcinomas (three prolactin-
 secreting and two ACTH-secreting) and three patients 
with aggressive pituitary tumors (one prolactin-secreting 
and two ACTH-secreting), received 4–24 cycles of orally 
administered temozolomide. Three patients responded 
to temozolomide, demonstrated by appreciable tumor 
shrinkage and reduced hormone secretion. MGMT 
expression did not predict tumoral response to temo-
zolomide, because it was positive in one responder and 
negative in two nonresponders. Toxicity remained mild 
in all patients. Tumoral and/or hormonal response to 
temozolomide treatment has always been observed soon 
after treatment initiation in responder patients, and the 
absence of response after three cycles of treatment con-
sistently predicted resistance to this treatment.119 Unfor-
tunately, initial response to temozolomide treatment is 
not always associated with long-term control, as a few 
cases showed tumor regression within 5–6 months after 
treatment initiation.121,122
Gene therapy
Gene therapy might represent a future option to treat 
aggressive pituitary adenomas but presently is still at an 
early stage of investigation.6 The available approaches 
include gene-directed enzyme therapy, in which the gene 
encoding thymidine kinase is delivered to tumoral cells, 
together with systemic administration of a nucleoside 
analogue, such as ganciclovir. The nucleoside analogue 
is subsequently locally transformed into an active cyto-
toxin by thymidine kinase. When prolactinomas are tar-
geted, expression of the gene encoding thymidine kinase 
is driven by the human prolactin (or cytomegalovirus) 
promoter.123–125
Conclusions
Nowadays, medical therapy with dopamine agonists is 
con sidered the gold standard of treatment in the vast 
major ity of patients with prolactinomas, given its broad 
suc cess in terms of control of prolactin excess and tumor 
shrinkage associated with minimal mor bidity. The safety 
issue of cardiac valve disease following caber goline 
therapy in patients with prolactinomas still requires 
some investigation. However, preliminary results seem 
to re assure that low doses of this drug, as used in patients 
with prolactinomas, are not detrimental for the cardio-
vascular system. Moreover, medical therapy seems not 
to be necessary throughout life; in some cases (20–60% 
in different series with varying follow-up and treat-
ment), the dopamine agonist can be withdrawn with-
out a recurrence of hyperprolactinemia or regrowth 
of prolactinomas. Only a small proportion of patients 
with hyperprolactinemia (10% in ca bergoline-treated 
cohorts, 20% in bromocriptine-treated cohorts) do not 
respond successfully to dopamine agonists. Absence 
of prolactin control and of tumor shrinkage indicates 
resistance to these drugs, which represents a challeng-
ing condition because of poor response to nonmedical 
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approaches, including transsphenoidal surgery and 
radiotherapy. Investigations are currently focusing on 
new treatment options but presently, however, resis-
tance to dopamine agonist remains a difficult-to-treat 
condition, and tumor progression to malignancy is pos-
sible. As a result, patients with tumors resistant to dopa-
mine agonists deserve particular attention and careful 
follow-up.
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